Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin | Zendy

Nick S. Laursen | Zendy; Robert H. Friesen | Zendy; Xueyong Zhu | Zendy; Mandy Jongeneelen | Zendy; Sven Blokland | Zendy; Jan Vermond | Zendy; Alida van Eijgen | Zendy; Chan Tang | Zendy; Harry A. van Diepen | Zendy; Galina Obmolova | Zendy; Marijn van der Neut Kolfschoten | Zendy; David Zuijdgeest | Zendy; Roel Straetemans | Zendy; Ryan M. B. Hoffman | Zendy; Travis Nieusma | Zendy; Jesper Pallesen | Zendy; Hannah L. Turner | Zendy; Steffen M. Bernard | Zendy; Andrew B. Ward | Zendy; Jinquan Luo | Zendy; Leo L. M. Poon | Zendy; Anna P. Tretiakova | Zendy; James M. Wilson | Zendy; Maria P. Limberis | Zendy; Ronald Vogels | Zendy; Boerries Brandenburg | Zendy; Joost A. Kolkman | Zendy; Ian A. Wilson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin

Author(s) -

Nick S. Laursen,

Robert H. Friesen,

Xueyong Zhu,

Mandy Jongeneelen,

Sven Blokland,

Jan Vermond,

Alida van Eijgen,

Chan Tang,

Harry A. van Diepen,

Galina Obmolova,

Marijn van der Neut Kolfschoten,

David Zuijdgeest,

Roel Straetemans,

Ryan M. B. Hoffman,

Travis Nieusma,

Jesper Pallesen,

Hannah L. Turner,

Steffen M. Bernard,

Andrew B. Ward,

Jinquan Luo,

Leo L. M. Poon,

Anna P. Tretiakova,

James M. Wilson,

Maria P. Limberis,

Ronald Vogels,

Boerries Brandenburg,

Joost A. Kolkman,

Ian A. Wilson

Publication year - 2018

Publication title -

science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 12.556

H-Index - 1186

eISSN - 1095-9203

pISSN - 0036-8075

DOI - 10.1126/science.aaq0620

Subject(s) - hemagglutinin (influenza) , virology , h5n1 genetic structure , antibody , influenza a virus , biology , medicine , virus , covid-19 , immunology , infectious disease (medical specialty) , disease , pathology

Durable influenza protection Vaccines are indispensable for the control and prevention of influenza, but there are several challenges to efficacy. Some individuals respond poorly to vaccination, and virus variation makes targeting optimal antigens difficult. Broadly neutralizing antibodies are one solution, but they have their own pitfalls, including limited cross-reactivity to both influenza A and B strains and the need for repeated injections. Now, Laursenet al. have developed multidomain antibodies with breadth and potency. Administered intranasally to mice with an adeno-associated virus vector, the antibodies provided durable and continuous protection from a panoply of influenza strains.Science , this issue p.598

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research